PRIORIX 3 Log10CCID50/0.5 mL+ 3.7 Log10CCID50/0.5 mL+ 3 Log10CCID50/0.5 mL prašak i rastvarač za rastvor za injekciju u napunjen Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

priorix 3 log10ccid50/0.5 ml+ 3.7 log10ccid50/0.5 ml+ 3 log10ccid50/0.5 ml prašak i rastvarač za rastvor za injekciju u napunjen

evropa lijek pharma d.o.o. - kombinovana пропорциональному protiv morbila, parotitisa sam rubeole, ziva, atenuisana - prašak i rastvarač za rastvor za injekciju u napunjenoj šprici - 3 log10ccid50/0.5 ml+ 3.7 log10ccid50/0.5 ml+ 3 log10ccid50/0.5 ml - 1 doza (0,5 ml) rastvora za injekciju sadrži: 3,0 log ccid50 živi atenuisani virus morbila (schwarz soj); 3,7 log ccid50 živi atenuisani virus parotitisa (rit 4385 soj); 3,0 log ccid50 živi atenuisani virus rubele (wistar ra 27/3 soj)

PRIORIX 3 Log10CCID50/0.5 mL+ 3,7 Log10CCID50/0.5 mL+ 3 Log10CCID50/0.5 mL prašak i rastvarač za rastvor za injekciju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

priorix 3 log10ccid50/0.5 ml+ 3,7 log10ccid50/0.5 ml+ 3 log10ccid50/0.5 ml prašak i rastvarač za rastvor za injekciju

evropa lijek pharma d.o.o. - kombinovana пропорциональному protiv morbila, parotitisa sam rubeole, ziva, atenuisana - prašak i rastvarač za rastvor za injekciju - 3 log10ccid50/0.5 ml+ 3,7 log10ccid50/0.5 ml+ 3 log10ccid50/0.5 ml - 1 doza (0,5 ml) sadrži: 3,0 log ccid50 živi atenuirani virus morbila (soj schwarz); 3,7 log ccid50 živi atenuirani virus parotitisa (soj rit 4385 dobiven iz soja jeryl lynn); 3,0 log ccid50 živi atenuirani virus rubeole (soj wistar ra 27/3).

Tecvayli Europska Unija - hrvatski - EMA (European Medicines Agency)

tecvayli

janssen-cilag international n.v. - teclistamab - multipli mijelom - antineoplastična sredstva - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Ebvallo Europska Unija - hrvatski - EMA (European Medicines Agency)

ebvallo

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Pedmarqsi Europska Unija - hrvatski - EMA (European Medicines Agency)

pedmarqsi

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - svi ostali terapeutski proizvodi - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.

Briumvi Europska Unija - hrvatski - EMA (European Medicines Agency)

briumvi

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Talvey Europska Unija - hrvatski - EMA (European Medicines Agency)

talvey

janssen-cilag international n.v. - talquetamab - multipli mijelom - antineoplastična sredstva - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.